Current therapeutic approaches for these diseases, such as anti-VEGF (vascular endothelial growth factor) therapy for neovascular AMD, complement inhibitors like pegcetacoplan for dry AMD, laser photocoagulation for DR, and intraocular pressure-lowering medications for glaucoma, present limitations [8,9,10]. This evidence concerns the gene VEGFA and dry age related macular degeneration.